Inflammatory Cardiovascular Risk Markers in Women with Hypopituitarism
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Patients with hypopituitarism have increased cardiovascular mortality. A high prevalence of conventional cardiovascular risk factors, including obesity, central fat distribution, insulin resistance, and dyslipidemia, have been described in these patients. The inflammatory markers C-reactive protein (CRP) and IL-6 are predictors of cardiovascular events, and high levels of CRP have been reported in men with hypopituitarism and GH deficiency. However, little is known about inflammatory cardiovascular risk markers in women with hypopituitarism. We therefore investigated whether inflammatory and traditional cardiovascular risk markers are elevated in women with hypopituitarism. Fifty-three women with hypopituitarism and 111 healthy control women were included in this cross-sectional study. Morning blood samples were drawn after an overnight fast. Serum was assayed for CRP, IL-6, glucose, insulin, IGF-I, triglycerides, total cholesterol, low density lipoprotein cholesterol, high density lipoprotein (HDL) cholesterol, lipoprotein(a), E2, total testosterone (total T) and free testosterone (free T), and dehydroepiandrosterone sulfate. IL-6 and CRP levels were higher in women with hypopituitarism than in healthy controls (P < 0.0001 for comparison between groups). In a multivariate model, CRP levels depended on hypopituitarism, body mass index (BMI), and estrogen use. There was an interaction between the effect of BMI and hypopituitarism on CRP levels, such that the importance of hypopituitarism in determining CRP levels disappeared at high BMIs. In a similar multivariate model, IL-6 levels depended on hypopituitarism and BMI. Total cholesterol, the total to HDL cholesterol ratio, and triglycerides were higher in hypopituitary patients, but only triglycerides and the total to HDL cholesterol ratio depended on hypopituitarism when controlling for BMI. There was no significant difference in lipoprotein(a) levels between hypopituitary women and control subjects. However, when controlling for estrogen use, lipoprotein(a) levels showed a trend toward being lower in the hypopituitary group (P = 0.075). In patients with hypopituitarism, CRP correlated negatively with IGF-I (r = -0.35; P = 0.010), total T (r = -0.42; P = 0.0020), and free T (r = -0.30; P = 0.031). Similarly, IL-6 correlated negatively with total T (r = -0.39; P = 0.0040) and androstenedione (r = -0.27; P = 0.048) in hypopituitary patients. In conclusion, hypopituitary women have increased levels of IL-6 and CRP, both of which are inflammatory markers of atherosclerosis. GH deficiency and androgen deficiency may contribute to these findings. Chronic inflammation may contribute to the high cardiovascular risk seen in this population.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Altered body composition, insulin resistance, hypertension, unfavorable lipid profile, endothelial dysfunction and atherosclerosis have been found in several studies on patients with long-term GHD (74,76,77,(82)(83)(84)(85)(86)(87).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [87]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-α,in Vivo1
Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D. R., Miles, J. M., Yudkin, J. S., Klein, S., & Coppack, S. W. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4450 · Cited by 2,012
Koenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,964
Ridker, P. M., Buring, J. E., Shih, J., Matias, M., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.98.8.731 · Cited by 1,642
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F., & Braunwald, E. (1999) · Circulation · doi:10.1161/01.cir.100.3.230 · Cited by 1,478
Cited by
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., Shalet, S. M., Vance, M. L., & for The Endocrine Society’s Clinical Guidelines Subcommittee (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2227 · Cited by 424
Mortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Cappola, A. R., Xue, Q.-L., Ferrucci, L., Guralnik, J. M., Volpato, S., & Fried, L. P. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021694 · Cited by 286
“Adults with panhypopituitarism who are sufficiently replaced for all pituitary hormones except GH have been shown to have high levels of IL-6 (36).”
BackgroundPituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach
Tanriverdi, F., Schneider, H. J., Aimaretti, G., Masel, B. E., Casanueva, F. F., & Kelestimur, F. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1065 · Cited by 218
Mouliou, D. S. (2023) · Diseases · doi:10.3390/diseases11040132 · Cited by 160
Takahashi, Y., Iida, K., Takahashi, K., Yoshioka, S., Fukuoka, H., Takeno, R., Imanaka, M., Nishizawa, H., Takahashi, M., Seo, Y., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.024 · Cited by 175
Vongpatanasin, W., Tuncel, M., Wang, Z., Arbique, D., Mehrad, B., & Jialal, I. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00156-6 · Cited by 153
“in patients with hypopituitarism (19), and adult-onset”
Gazzaruso, C., Gola, M., Karamouzis, I., Giubbini, R., & Giustina, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2394 · Cited by 151
“Bollerslev et al (70) showed that GH replacement was associated with reduced CRP, independently of weight or immune-modulating actions, even greater than that observed in a previous controlled study that enrolled only women (71).”
BackgroundResultThe role of hormones, cytokines and heat shock proteins during age-related muscle loss
Lee, C. E., McArdle, A., & Griffiths, R. (2007) · Clinical Nutrition · doi:10.1016/j.clnu.2007.05.005 · Cited by 159
Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk
Joseph, C., Kenny, R. A., Taxel, P., Lorenzo, J., Duque, G., & Kuchel, G. A. (2005) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.01.004 · Cited by 146
Davison, S. L., & Davis, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021929 · Cited by 142
Sesmilo, G. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1692 · Cited by 116
“Based on these results and our previous studies in GH-deficient patients (21, 33), we propose that the GH/IGF-I axis is an important determinant of FIG.”
BackgroundResultSelf-citationAttanasio, A. F., Mo, D., Erfurth, E. M., Tan, M., Ho, K. Y., Kleinberg, D., Zimmermann, A. G., & Chanson, P. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1326 · Cited by 115
“Such higher risk in females has been reported in adult hypopituitary GHD patients (30, 31), and a recent study in 750 adult Swedish GHD patients found an increased prevalence of type 2 diabetes mellitus in women compared with men (32), suggesting that aspects specifically related to GHD or hypopituitarism may contribu…”
BackgroundReingold, J. S., Wanke, C., Kotler, D. P., Lewis, C. E., Tracy, R., Heymsfield, S., Tien, P. C., Bacchetti, P., Scherzer, R., Grunfeld, C., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181685727 · Cited by 106
“Conversely, CRP levels are relatively elevated in persons who are deficient in growth hormone and correct with growth hormone replacement therapy.(39,40) These findings suggest that CRP may not be as good an indicator of CVD risk in persons with abnormal levels of growth hormone, because these conditions affect CRP in…”
BackgroundBeauregard, C., Utz, A. L., Schaub, A. E., Nachtigall, L., Biller, B. M. K., Miller, K. K., & Klibanski, A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2371 · Cited by 99
Self-citationTruncal Adiposity, Relative Growth Hormone Deficiency, and Cardiovascular Risk
Miller, K. K., Biller, B. M. K., Lipman, J. G., Bradwin, G., Rifai, N., & Klibanski, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0894 · Cited by 87
Self-citationRadiation-induced hypopituitarism
Fernandez, A., Brada, M., Zabuliene, L., Karavitaki, N., & Wass, J. A. H. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0231 · Cited by 84
“Increased inflammatory markers (Sesmilo et al .”
Goldstein, J. M., Handa, R. J., & Tobet, S. A. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.12.001 · Cited by 77
“In clinical studies, IGF-1 was inversely proportional to high sensitivity Creactive protein, a critical inflammatory CVD risk indicator (Sesmilo et al., 2001; Lawson et al., 2007).”
Yuen, K. C. J., Frystyk, J., White, D. K., Twickler, T. B., Koppeschaar, H. P. F., Harris, P. E., Fryklund, L., Murgatroyd, P. R., & Dunger, D. B. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02359.x · Cited by 67
Miller, K. K., Wexler, T., Fazeli, P., Gunnell, L., Graham, G. J., Beauregard, C., Hemphill, L., Nachtigall, L., Loeffler, J., Swearingen, B., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1611 · Cited by 66
Self-citationIncrease of Classic and Nonclassic Cardiovascular Risk Factors in Patients with Acromegaly
Vilar, L., Naves, L. A., Costa, S. S., Abdalla, L. F., Coelho, C. E., & Casulari, L. A. (2007) · Endocrine Practice · doi:10.4158/ep.13.4.363 · Cited by 67
Colao, A., Di Somma, C., Rota, F., Pivonello, R., Savanelli, M. C., Spiezia, S., & Lombardi, G. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2247 · Cited by 62
Deepak, D. S., Daousi, C., Javadpour, M., Clark, D. J., PERRY, Y. S., Pinkney, J. H., & MacFarlane, I. A. (2010) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2010.02.002 · Cited by 62
Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]
Giovannini, L., Tirabassi, G., Muscogiuri, G., Somma, C. D., Colao, A., & Balercia, G. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0337 · Cited by 64
Utz, A. L., Yamamoto, A., Hemphill, L., & Miller, K. K. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0169 · Cited by 57
Self-citationCardiovascular risk factors in middle-aged women with subclinical hypothyroidism.
Luboshitzky, R., & Herer, P. (2004) · PubMed · Cited by 72
The allopregnanolone to progesterone ratio across the menstrual cycle and in menopause
Kimball, A., Dichtel, L. E., Nyer, M., Mischoulon, D., Fisher, L. B., Cusin, C., Dording, C. M., Trinh, N., Yeung, A., Haines, M. S., et al. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104512 · Cited by 54
“Clinical characteristics of the premenopausal subjects have been reported as part of larger groups in parent studies (Miller et al., 2004, 2001; Sesmilo et al., 2001), but neither allopregnanolone levels nor progesterone levels by GC/MS have been reported for any subject in any parent study or subset analysis.”
BackgroundSelf-citationSha, J., Qie, G., Yao, Q., Sun, W., Wang, C., Zhang, Z., Wang, X., Wang, P., Jiang, J., Bai, X., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.607059 · Cited by 58
“Age, Median(IQR), y 47 (37, 51) 46 (38, 50) 0.”
BackgroundInfluentialUncoupling of cardiovascular risk markers in adolescent girls with anorexia nervosa
Misra, M., Miller, K. K., Tsai, P., Stewart, V., End, A., Freed, N., Herzog, D. B., Goldstein, M. A., Riggs, S., & Klibanski, A. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.08.043 · Cited by 53
Self-citationFilipsson, H., & Johannsson, G. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0319 · Cited by 50
Leonsson, M., Hulthe, J., Johannsson, G., Wiklund, O., Wikstrand, J., Bengtsson, B. Å., & Oscarsson, J. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01832.x · Cited by 50
“E-mail: maria.leonsson@medic.gu.se © 2003 Blackwell Publishing Ltd, Clinical Endocrinology, 59, 242–250 CRP and IL-6 have been found in GHD patients (Serri et al., 1999; Sesmilo et al., 2001).”
BackgroundResultInfluentialSchut, A. F., Janssen, J. A. M. J. L., Deinum, J., Vergeer, J., Hofman, A., Lamberts, S. W. J., Oostra, B. A., Pols, H. A. P., Witteman, J. C. M., & van Duijn, C. M. (2003) · Stroke · doi:10.1161/01.str.0000076013.00240.b0 · Cited by 54
Capalbo, D., Raso, G. M., Esposito, A. A., Mase, R. D., Barbieri, F., Meli, R., Bruzzese, D., & Salerno, M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12393 · Cited by 47
Nyström, H. F., Barbosa, E. J. L., Nilsson, A. G., Norrman, L.-L., Ragnarsson, Ó., & Johannsson, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2006 · Cited by 45
Makimura, H., Stanley, T. L., Mun, D., Chen, C. S., Wei, J., Connelly, J. M., Hemphill, L., & Grinspoon, S. K. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1295 · Cited by 45
Lin, E., Wexler, T. L., Nachtigall, L., Tritos, N., Swearingen, B., Hemphill, L., Loeffler, J., Biller, B. M. K., Klibanski, A., & Miller, K. K. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04361.x · Cited by 37
Self-citationMetabolic alterations in patients who develop traumatic brain injury (TBI)-induced hypopituitarism
Prodam, F., Gasco, V., Caputo, M., Zavattaro, M., Pagano, L., Marzullo, P., Belcastro, S., Busti, A., Perino, C., Grottoli, S., et al. (2013) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2013.04.001 · Cited by 35
“In particular, altered body composition, insulin resistance, hypertension, unfavorable lipid profile, endothelial dysfunction and atherosclerosis has been reported in several studies on treatment of naïve GH deficient patients along time [6–8,11–16].”
BackgroundAbdu, T. A. M., Elhadd, T. A., Buch, H., Barton, D. M., Neary, R. H., & Clayton, R. N. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02109.x · Cited by 35
“Recent studies reported increased CRP and IL-6 levels in hypopituitary women and rGH replacement resulted in significant reduction in CRP and IL-6 in hypopituitary men (Sesmilo et al., 2000, 2001).”
BackgroundAndreassen, M., Frystyk, J., Faber, J., & Kristensen, L. O. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1009 · Cited by 33
Franco, C., Andersson, B., Lönn, L., Bengtsson, B., Svensson, J., & Johannsson, G. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0068 · Cited by 31
“It is also possible that the reduction in systemic inflammation by GH was mediated by the improvement of regional fat distribution (12).”
BackgroundRhee, Y., Paik, M., Kim, K.-R., Ko, Y., Kang, E. S., Soo, B., Lee, H. C., & Lim, S.-K. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.02.012 · Cited by 29
IGF‐I concentrations are positively associated with carotid artery atherosclerosis in women
Hietaniemi, M., Pöykkö, S. M., Ukkola, O. H., Päivänsalo, M. J., & Kesäniemi, Y. A. (2005) · Annals of Medicine · doi:10.1080/07853890510011967 · Cited by 29
“In our study, IGF-I concentration was inversely correlated with CRP, which has also been reported earlier (41,42).”
ResultHormonal and Nutritional Effects on Cardiovascular Risk Markers in Young Women
Lawson, E. A., Miller, K. K., Mathur, V. A., Misra, M., Meenaghan, E. M., Herzog, D. B., & Klibanski, A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0364 · Cited by 31
“In healthy populations, hsCRP has been found to be inversely proportional to IGF-I (6, 7).”
BackgroundSelf-citationSheehan syndrome: a current approach to a dormant disease
Karaca, Z., & Keleştimur, F. (2025) · Pituitary · doi:10.1007/s11102-024-01481-1 · Cited by 32
Bhat, M. A., Laway, B. A., Shah, Z. A., Wani, A. I., & Mubarik, I. (2014) · Pituitary · doi:10.1007/s11102-014-0575-8 · Cited by 28
“High levels of CRP have been reported in men and women with hypopituitarism of varying etiology which may independently predispose to increased cardiovascular morbidity [6, 7].”
BackgroundLinking Marital Support to Aging-Related Biomarkers: Both Age and Marital Quality Matter
Wilson, S. J., Bailey, B. E., Malarkey, W. B., & Kiecolt‐Glaser, J. K. (2019) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbz106 · Cited by 28
Sheehan syndrome: Cardiovascular and metabolic comorbidities
Laway, B. A., & Baba, M. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1086731 · Cited by 30
“In a cross-sectional study that enrolled 53 women with hypopituitarism and 111 healthy control women, interleukin-6 (IL-6) and CRP concentration were significantly higher in women with hypopituitarism than in healthy controls and were attributed to GH and estrogen deficiency (45).”
BackgroundMurray, R. D., Wieringa, G., Lawrance, J. A., Adams, J. E., & Shalet, S. M. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03754.x · Cited by 24
Andreassen, M., Vestergaard, H., & Kristensen, L. Ø. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02986.x · Cited by 24
Khang, A. R., Ku, E. J., Kim, Y. A., Roh, E., Bae, J. H., Oh, T. J., Kim, S. W., Shin, C. S., Kim, S. Y., & Kim, J. H. (2016) · Pituitary · doi:10.1007/s11102-016-0747-9 · Cited by 24
Höybye, C. (2006) · Hormone Research in Paediatrics · doi:10.1159/000093229 · Cited by 23
Krzyżanowska, K., Mittermayer, F., Schnack, C., Hofer, M., Wolzt, M., & Schernthaner, G.-H. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2005.01474.x · Cited by 19
Lo, J., You, S. M., Wei, J., Hron, B. M., & Grinspoon, S. K. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03603.x · Cited by 18
Graham, M., Davies, B., Kicman, A. T., Cowan, D., Hullin, D. A., & Baker, J. S. (2007) · Current Neurovascular Research · doi:10.2174/156720207779940699 · Cited by 17
“RhGH administration has been shown to lower HCY in GHD, without a correlation in hsCRP or Interleukin (IL)-6 (Sesmilo et al., 2001).”
BackgroundCastillo, A., Zantut‐Wittmann, D. E., Neto, A. M., Jales, R. M., & Garmes, H. M. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0649-8010 · Cited by 17
“After BMI pairing insulin sensitivity was similar in both groups [39].”
BackgroundMethodGarmes, H. M. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09872-8 · Cited by 16
“A study from our group demonstrated that hypopituitary patients without GHRT have more dyslipidemia, and higher PCR levels than a control group, paired by age, gender, and BMI [92].”
Cardiovascular Effects of Growth Hormone Treatment: Potential Risks and Benefits
Colao, A. (2004) · Hormone Research in Paediatrics · doi:10.1159/000080498 · Cited by 16
Andreassen, M., Raymond, I. E., Hildebrandt, P. R., Kistorp, C., Rathcke, C. N., Vestergaard, H., Faber, J. O., & Kristensen, L. Ø. (2010) · Inflammation Research · doi:10.1007/s00011-009-0154-z · Cited by 13
“In support of this suggestion, studies in patients with primary growth hormone disturbances, investigated before and after normalisation of IGF-I, have indicated that levels of GH and IGF-I inversely influenced levels of inflammatory markers [25–27].”
ResultAlbert, S. G., Haas, M. J., & Mooradian, A. D. (2006) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2006.10.001 · Cited by 13
“Patients with complete or partial hypopituitarism and growth hormone deficiency (GHD) have abnormal body fat composition [7,8] and abnormal serum levels of the adipokines and inflammatory cytokines [9–11].”
BackgroundÖzbey, N., Telci, A., Çakatay, U., Yurçi, A., & Molvalilar, S. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03348199 · Cited by 15
Growth hormone deficiency and cardiovascular risk: do we need additional markers?
Gola, M., & Giustina, A. (2012) · Endocrine · doi:10.1007/s12020-012-9769-x · Cited by 12
Graham, M. R., Baker, J. S., Evans, P., Kicman, A. T., Cowan, D., Hullin, D. A., & Davies, B. (2007) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2007.01.010 · Cited by 11
“RhGH administration has also lowered HCY in GHD, without a correlation in CRP or interleukin (IL)-6 [40], unlike this study where HCY and CRP have both significantly decreased.”
ResultHuan, C., Wang, M., Song, Y., Jia, Z., Wei, D., Wang, L., Xu, Q., Wang, J., Zhao, M., Geng, J., et al. (2023) · Andrology · doi:10.1111/andr.13544 · Cited by 10
“35 However, it is unclear whether natu-ralendogenoustestosteroneandandrostenedioneareassociatedwith reducing aforementioned inflammatory markers.”
BackgroundHypopituitarism and Cardiovascular Risk
Kraljević, I., Solak, M., Mandić, A., Kozamernik, K. M., Raičević, M., Divanović, A., Kovačević, Z., & Muzurović, E. M. (2025) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484251332398 · Cited by 10
“The majority of CV risk in hypopituitarism can be attributed to a cluster of classic CV risk factors such as obesity, glucose intolerance, dyslipidemia, and hypertension resulting from under-or over-replacement with hormones, 4 as shown in Figure 1.”
Neuroendocrine manifestations of Erdheim–Chester disease
Manaka, K., Sato, J., & Makita, N. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-820683-6.00010-5 · Cited by 8
Lindboe, J. B., Langkilde, A., Eugen‐Olsen, J., Hansen, B. R., Haupt, T. H., Petersen, J., & Andersen, O. (2016) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2016.1201722 · Cited by 8
“CRP has previously been shown to be increased in growth hormone deficient adults and in untreated hypopituitarism.[34,35] Furthermore, acromegaly patients show reduced CRP levels compared to controls.”
BackgroundYurçi, A., Oflaz, H., Meriç, M., & Özbey, N. (2005) · Hormone Research in Paediatrics · doi:10.1159/000088336 · Cited by 8
“Consequently in healthy subjects IGF-1 may offer protective effects on myocardial structure and performance. Increased E m which indicates improved diastolic performance in association with increased IGF-1 may reflect favorable effects of IGF-1 on the myocardium in healthy persons.Several cardiovascular disease risk f…”
BackgroundCapatina, C. A.-M., & Wass, J. A. H. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.11.002 · Cited by 9
Hypopituitarism and Growth Hormone Deficiency
Burt, M. G., & Ho, K. K. Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00011-1 · Cited by 9
Growth hormone dosing variables in growth hormone-deficient adults
Cook, D. M., & Yuen, K. C. J. (2006) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2006.03.007 · Cited by 6
Höybye, C., Faseh, L., Himonakos, C., Pielak, T., & Eugen‐Olsen, J. (2019) · Endocrine Connections · doi:10.1530/ec-19-0159 · Cited by 6
Effect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels
Seki, Y., Morimoto, S., Bokuda, K., Watanabe, D., Yamashita, K., Takano, N., Amano, K., Kawamata, T., & Ichihara, A. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad137 · Cited by 5
“Patients with hypopituitarism have been observed to exhibit elevated CRP levels [11 ].”
BackgroundIsotton, A. L., Wender, M. C. O., & Czepielewski, M. A. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000500023 · Cited by 10
Influence of Growth Hormone on Cardiovascular Health and Disease
Colao, A., Somma, C. D., Vitale, G., Filippella, M., & Lombardi, G. (2003) · Treatments in Endocrinology · doi:10.2165/00024677-200302050-00006 · Cited by 5
“The improved cardiac performance was have been reported both in men[53] and women[54] with GHD, also sustained by a remarkable increase in exercise performance.”
BackgroundLim, H. H., Kang, M. J., Yun, I. S., Lee, Y. A., Shin, C. H., & Yang, S. W. (2010) · Korean Journal of Pediatrics · doi:10.3345/kjp.2010.53.10.892 · Cited by 5
Muscogiuri, G., Albertelli, M., Arnaldi, G., Barrea, L., Bellastella, G., Bonomi, M., Caputo, M., Caprio, M., Cignarelli, A., Gioia, L. D., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02862-y · Cited by 4
“Moreover, adipose tissue dysfunction in GHD amplifies pro-atherogenic mech - anisms through the dysregulated secretion of inflammatory cytokines and adipokines such as leptin, which influence insulin sensitivity and lipid storage [64, 65].”
Gupta, S., Dayal, D., Rohit, M. K., Gawalkar, A. A., Raj, K. M., Attri, S. V., Sachdeva, N. K., & Kaur, H. (2022) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2021-0693 · Cited by 4
Willemsen, R. H., Mulder, P. G. H., van Toorenenbergen, A. W., & Hokken‐Koelega, A. C. S. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03019.x · Cited by 4
Soy Supplement: Why Is the Effect So Elusive?
Albertazzi, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.7.8587 · Cited by 3
Klinc, A., Janež, A., & Jensterle, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052010 · Cited by 2
“In addition, a few studies, including ours, have established a negative between IGF-1 and hs-CRP levels [4,17,21,23], supporting a direct effect of GHRT on However, suggesting systemic composition. study is the first to demonstrate the association between long-term maintenance of IGF-1 SDS within…”
Ricart, W., & Fernández‐Real, J. M. (2003) · Medicina Clínica · doi:10.1016/s0025-7753(03)73792-0 · Cited by 2
Science of Nonalcoholic Fatty Liver Disease in Anti-Aging Medicine 2011
Sumida, Y., Naito, Y., Hashimoto, E., Aoi, W., Takahashi, Y., Yonei, Y., & Yoshikawa, T. (2012) · Anti-aging Medicine · doi:10.3793/jaam.9.24 · Cited by 2
Postradiation therapy hypopituitarism
Hatipoğlu, B., & Kennedy, L. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.82 · Cited by 2
Aspects of diagnosis and treatment of hypopituitarism in adult life
Nyström, H. F. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 2
Kim, S.-W., Chung, Y., Lee, E. J., & Kim, S. Y. (2006) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2006.21.6.460 · Cited by 2
“성장호르몬 결핍증 환자에서 염증반응 표지자들이 증가 되어 있다[65,66].”
Excess Vascular Mortality in Hypopituitarism: Is it the Result of Estrogen or GH Deficiency?
Elhadd, T., Abdu, T. A. M., & Clayton, R. N. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3509 · Cited by 2
Iglesias, P. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2649164 · Cited by 1
Management of growth hormone deficiency in adults
Bujanova, J., & Cummings, M. H. (2015) · Prescriber · doi:10.1002/psb.1422 · Cited by 1
Freqüência de fatores de risco cardiovascular clássicos e não-clássicos em portadores de acromegalia
Filho, R., & Vilar, L. (2007)
Fiszlejder, L., & Fiszlejder, P. (2012) · Revista Argentina de Endocrinología y Metabolismo
The GH-IGF-1 Axis in Postmenopausal Women with Abdominal Obesity
Ramos, C. F. (2007) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Hypopituitarism and Growth Hormone Deficiency
Lee, P., & Ho, K. K. Y. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00013-7 · Cited by 2
Pérez, J. Á. D., Rodríguez-Hervada, A. D., de la Vega, I. R., & Novoa, M. P. D. M. (2004) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(04)70111-3
Cardiovascular and Metabolic Comorbidities in Pituitary Disorders
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5034-2
Sun, Y., Zhang, Y., Luan, T., Li, R., Cai, D., & Zhang, W. (2025) · Mammalian Genome · doi:10.1007/s00335-025-10169-1
Metabolic implications of reduced growth hormone availability in abdominal obesity
Buijs, M. M. (2003) · Cited by 1
Avaliação do estresse oxidativo e dos marcadores inflamatorios em pacientes hiperlipidemicos
Vasconcelos, E. M. D. A. (2007) · doi:10.47749/t/unicamp.2007.398230
Metadata
- Authors
- Sesmilo, G., Miller, K. K., Hayden, D., & Klibanski, A.
- Affiliations
- Harvard University (US)
- Corresponding author
- Klibanski, Anne
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-12
- Volume
- 86
- Issue
- 12
- Pages
- 5774-5781
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2133640045
- Cited by
- 97
- References
- 38
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 1 · 2021: 2 · 2019: 3 · 2018: 1 · 2016: 2 · 2015: 4 · 2014: 2 · 2013: 4 · 2012: 6
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Massachusetts General Hospital
- National Center for Research Resources (M01RR001066, M01-RR01066)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- hypopituitarism, cardiovascular risk markers, inflammation, C-reactive protein, interleukin-6, women, body mass index, estrogen use, lipoprotein(a), insulin-like growth factor I, testosterone, dyslipidemia, cardiovascular mortality, growth hormone deficiency, obesity, insulin resistance, triglycerides, dehydroepiandrosterone sulfate, sex hormones
- MeSH terms
- Blood Glucose, C-Reactive Protein, Female, Humans, Hypopituitarism, Inflammation, Insulin, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Reference Values, Risk Factors, Triglycerides, Biomarkers, Interleukin-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.